Clinical Trial Update: Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 study of cicletanine for pulmonary arterial hypertension was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Cicletanine (cicletanine)

Snippet

Sponsor: Gilead Sciences | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED